Events & Presentations
Board of Directors
Historic Stock Lookup
Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 8, 2017 | Press Release
View Presentation: GR-MD-02 Used in Combination Cancer Therapy from GTCBio 9th Immunotherapeutics & Immunomonitoring Conference
February 7, 2017 | Presentation
Combination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials
February 7, 2017 | Press Release
Why did you choose to become the CEO of Galectin Therapeutics?
Are you conducting clinical trials with GR-MD-02? What results have you seen so far?
Can you give me a quick overview of Galectin Therapeutics and the opportunity it sees for GR-MD-02?
Why are the results of the GR-MD-02 psoriasis study so promising?
Why is the NASH-CX trial so important?
See all videos
Galectin Therapeutics, Inc.
Financial Tear Sheet
Filings & Reports
Stock price updates every 30 minutes.
Latest Corporate Presentation
Media Fact Sheet
Corporate Fact Sheet
© 2017 Galectin Therapeutics Inc. - All Rights Reserved
Disclaimer: This site may contain